Episode summary
AstraZeneca's CFO on GLP-1 Drugs, AI, and More | At Barron's
At Barron's
· · Hosts: Andy Serwer · Guests: Aradhana Sarin
Summary
AstraZeneca’s chief financial officer Aradhana Sarin said the company’s biggest near-term growth themes include an oral small-molecule GLP-1 drug, broader metabolic combinations, and a still-expanding oncology and biopharma pipeline. She said AstraZeneca expects to present phase 2 data on the oral GLP-1 soon and move it into phase 3, while differentiating itself by targeting patients with metabolic disease and co-morbidities rather than weight loss alone.
Sarin defended management’s long-term goal of reaching $80 billion in revenue by 2030, saying the target was ambitious when set in 2024 but now looks more plausible as consensus estimates have moved higher. She said the growth is intended to be organically driven, with licensing deals only in early-stage programs, and that AstraZeneca is prioritizing R&D based on unmet need, scientific derisking, and commercial potential. She also said AI is not yet central to capital-allocation decisions, but is increasingly being used to improve clinical-trial design and patient targeting.
She argued that AstraZeneca’s U.S. listing change to regular shares on the NYSE should broaden its investor base, and said the company’s regionalized manufacturing network should help it manage tariffs and supply-chain pressure. On pricing, she said the industry’s MFN agreement could lower U.S. drug costs while pushing countries to spend more on innovative medicines. Sarin also said the Alexion acquisition has outperformed expectations and helped AstraZeneca build a larger rare-disease franchise.
Key takeaways
- Aradhana Sarin said AstraZeneca’s oral small-molecule GLP-1 is headed toward phase 3 after upcoming phase 2 data.
- Sarin said the company’s $80 billion revenue target for 2030 is now closer to consensus estimates and remains organically driven.
- She said biopharma, especially cardiovascular-renal drugs, is likely to become a major growth driver alongside oncology.
- Sarin said AstraZeneca is using AI more in clinical-trial design than in final R&D capital-allocation decisions.
- She said the Alexion acquisition has lifted AstraZeneca’s rare-disease business to more than $9 billion and expanded it globally.
Notable quotes
“we will be presenting soon uh the phase 2 data from that and expect to move that into phase three”
“the next phase of growth that we'll see is actually going to come from bioarma”
“not quite yet in that decision-making process because like you said there's there are a lot of variables”
“I think there's a lot of growth still to come”
How the episode opens
With all the action in pharma these days in GLP-1 drugs, it's sometimes difficult for the rest of the industry to garner attention. Recently, I sat down with Astroenica CFO ADA Serene. One question I asked was how our company is addressing the red-hot GLP-1 market, which at the moment is crowded with injectable drugs.
All the action seems to be in GLP-1 drugs. So, how do you keep up with the Joneses over there? those companies that feature those particular drugs.
Yeah. So we are uh also have our own uh GLP-1 medicine development. Um the drugs in the market today are injectable and we have what is an oral small molecule GLP-1.
So not a peptide GLP-1 but a small molecule oral GLP-1. And uh we will be presenting soon uh the phase 2 data from that and expect to move that into phase three. Um and again for oral medicines there's not a lot of companies that have oral medicines really only one competitor ahead of us.
The other thing where we think is really differentiated is uh you know GLPs have been used mostly for for weight loss or diabetes management. But when you look at the patients that uh that uh have metabolic disease so you know as a as a bigger umbrella many of them or most of them actually have one to two coorbidities. So patients will have um not only weight management issues but either hypertension or dysipidemia or other sort of coorbidities.
And so what we're developing is combinations that allows us to treat uh the patient holistically with those co-orbidities as well. So that's a very unique angle.
Astroenica's push into GLP1s is key to its efforts to reach $80 billion of revenue by 2030. But when CEO Pascal Sorio first announced that target, backed by plans for 20 new medicines, Wall Street was skeptical.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- glp-1 drugs
- cfo outlook
- ai in healthcare
- capital spending
- drug pipeline
Companies and tickers mentioned
- AZN
- AstraZeneca
Watch the episode
Watch “AstraZeneca's CFO on GLP-1 Drugs, AI, and More | At Barron's” on YouTube
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from At Barron's
-
Kai-Fu Lee on How AI Can Help Grow a Company's Earnings -
Rocket CEO: "Homeowners Are Still Waiting to Buy Homes" -
Moderna CEO on the Biotech’s Cancer Vaccine and Pipeline -
Anthony Scaramucci on Katie Zacharia, Trump, and the Midterms | At Barron's -
IMAX CEO on 'The Odyssey,' Chris Nolan, and Company's Sudden Ascent | At Barron's -
PG&E's CEO on Data Centers, Energy Rates, and the Stock | At Barron's
At Barron's, this episode and its artwork belong to At Barron's. Octagon is not affiliated with the show; this page is an independent summary.
